Trial reportBMC nephrology2013
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
Trial report in BMC nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 6 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).The Cochrane database of systematic reviews · 2025Pooled it
- Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.Renal failure · 2021Pooled it
- Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).The Cochrane database of systematic reviews · 2018Pooled it
- Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.PloS one · 2017Pooled it
- Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.PloS one · 2016Pooled it
- Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.BMC nephrology · 2013Pooled it
- Correcting serum phosphate homeostasis does not alleviate the health dangers of high phosphate consumption.Journal of translational medicine · 2026Article
- A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials.Scientific reports · 2025Article
- Effect of cerium oxide on iron metabolism in mice.Journal of clinical biochemistry and nutrition · 2024Article
- Evaluation of cerium oxide as a phosphate binder using 5/6 nephrectomy model rat.BMC nephrology · 2022Article
- Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia.African health sciences · 2022Observational
- Frequent Involvement of the Duodenum with Lanthanum Deposition: A Retrospective Observational Study.Internal medicine (Tokyo, Japan) · 2019Observational
- NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.Kidney international reports · 2018Article
- Lanthanum carbonate: safety data after 10 years.Nephrology (Carlton, Vic.) · 2016Review
- Lanthanum-Induced Gastrointestinal Histiocytosis.ACG case reports journal · 2015Article
- The elements of life and medicines.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum phosphorus control is critical for chronic kidney disease (CKD) 5D patients. Currently, clinical profile for an oral phosphorus binder in the mainland Chinese population is not available.
objectiveTo establish the efficacy, safety, and tolerability of lanthanum carbonate in CKD 5D patients.
designMulticenter, randomized, double blind, placebo-controlled study. A central randomization center used computer generated tables to allocate treatments.
settingTwelve tertiary teaching hospitals and medical university affiliated hospitals in mainland China.
participantsOverall, 258 hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) adult patients were enrolled.
interventionAfter a 0-3-week washout period and a 4-week lanthanum carbonate dose-titration period, 230 patients were randomized 1:1 to receive lanthanum carbonate (1500 mg-3000 mg) or placebo for a further 4-week maintenance phase.
main outcome measuresEfficacy and safety of lanthanum carbonate to achieve and maintain target serum phosphorus concentrations were assessed.
resultsIn the titration phase, serum phosphorus concentrations of all patients decreased significantly. About three-fifths achieved target levels without significantly disturbing serum calcium levels. At the end of the maintenance period, the mean difference in serum phosphorus was significantly different between the lanthanum carbonate and placebo-treated groups (0.63±0.62 mmol/L vs. 0.15±0.52 mmol/L, P < 0.001). The drug-related adverse effects were mild and mostly gastrointestinal in nature.
conclusionLanthanum carbonate is an efficacious and well-tolerated oral phosphate binder with a mild AE profile in hemodialysis and CAPD patients. This agent may provide an alternative for the treatment of hyperphosphatemia in CKD 5D patients in mainland China.
trial registrationNo. ChiCTR-TRC-10000817.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.